Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. See why NVO stock is a Buy.

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find out why NVO stock is a hold.

Novo Nordisk (NVO-2.98%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...

Novo Nordisk's share price is down 54% from its peak in June 2024. Its U.S.-listed shares fell another 3% in premarket trading Friday. The company, headquartered in Bagsvaerd, ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo Nordisk is introducing a new cash-offer price of $299 available through July 31, 2025, and available for self-paying patients who are new to the Wegovy savings offer or those who have not ...

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

On April 29, Novo Nordisk (NVO 1.02%) and Hims & Hers Health (HIMS-5.46%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy.